Analyst consensus rating
Vivos Therapeutics Analyst Rating: Buy
VVOS is rated Buy by 3 analysts with a $2.12 target. As of 2026-08-31.
Direct answer
Vivos Therapeutics's consensus rating is Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $2.12.
Forecast evidence checked August 31, 2026.
Get free Vivos Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.22
- Average price target
- $2.12
- High price target
- $3.10
- Low price target
- $0.75
- Low target gap
- +233.5%
- Target upside
- +841.2%
- High target gap
- +1,278.4%
- Target range width
- 1,044.9%
- Consensus rating
- Buy
- Analysts
- 3
- Evidence date
- August 31, 2026
- Valid through
- September 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Vivos Therapeutics?
Vivos Therapeutics has a verified Buy consensus. The same dataset has an average price target of $2.12.
How far are Vivos Therapeutics's low and high targets from the recorded price?
The low target implies +233.5%, while the high target implies +1,278.4%.
How many analysts are included in Vivos Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is Vivos Therapeutics's target upside or downside calculated?
The average target of $2.12 is divided by the recorded price of $0.22, then one is subtracted to produce +841.2%. This does not guarantee a future return.
When was Vivos Therapeutics's analyst forecast verified?
The data was verified on 2026-08-31. The dataset is valid through 2026-09-07.